Psilocybin-Assisted Group Therapy for Depression with Matthew Hicks, ND, MS

Psilocybin-Assisted Group Therapy for Depression with Matthew Hicks, ND, MS

Author: Lynn Marie Morski, MD, JD October 29, 2025 Duration: 38:36

In this episode Matthew Hicks, ND, MS joins to dive into the topic of psilocybin-assisted group therapy for depression. Dr. Hicks is a research Investigator at the National University of Natural Medicine as well as a Naturopathic doctor and licensed psilocybin facilitator at Synaptic Institute.

In this conversation, Dr. Hicks shares findings from one of the first studies investigating psilocybin-assisted group therapy for depression, conducted in Oregon's new legal psilocybin framework. He explains how the high cost and labor-intensive nature of psychedelic therapy inspired him to explore a group model that could make treatment more financially accessible while preserving - and even enhancing - its therapeutic potential. Dr. Hicks describes the structure of the study and discusses how initial participant hesitancy about group work transformed into deep connection and shared healing. He also highlights the study's significant reductions in depression scores, improvements across quality-of-life measures, and the potential for group-based approaches to pave the way toward insurance reimbursement and broader access to psychedelic care.

 

In this episode, you'll hear:

  • Why affordability and accessibility were central motivations for developing a group-based psilocybin protocol
  • The benefits and challenges of conducting psilocybin sessions in a shared group setting
  • How Dr. Hicks' study balanced inclusion of low-income participants with safety and stability criteria
  • The details of the group treatment structure for Dr. Hicks' study
  • Why Dr. Hicks believes group formats may be inherently therapeutic in addition to their economic efficiency
  • Dr. Hicks's vision for future efficacy and cost-effectiveness studies that could enable insurance coverage

 

Quotes:

"In terms of the group dynamic, almost everyone in the intake process was very reluctant. They were trepidatious. They were a little worried about the group part of it. And almost everybody at the end of it, when we did the follow ups at the group, was amazing. People made friends. They felt really supported. They felt really seen by the process of hearing other people's journeys and the growth that they went through—and seeing some other examples of transformation was really powerful and was really encouraging to me." [10:29]

"So [there are] really positive aspects to doing this in a group format that's not just economic—it's not just cheaper to do this in group, it actually has therapeutic benefits that you miss out on when you only do this one on one." [11:12]

"That was always my question in the follow up sessions: 'did your participation in this study change the way you engaged in psychotherapy? Did it change the relationship with your therapist?' And a lot of people reported that it did. They felt they were able to open up and engage more deeply, be more introspective. And it did, in many cases, not all, improve their psychotherapy outcomes as well." [18:24]

"Some people reported that hearing someone else in the group crying for a bit really opened up something in them and they almost felt grateful for that. This other person is having a meaningful experience over there, and that's something they wouldn't have gotten on their own if they hadn't heard that person crying." [22:45]

 

Links:

Dr. Hicks on LinkedIn

Synaptic Institute website 

Dr. Hicks' research at Synaptic Institute

National University of Natural Medicine website 

Psychedelic Medicine Association

Porangui


Exploring the frontier of mind and medicine, the Psychedelic Medicine Podcast with Dr. Lynn Marie Morski delves into the complex world of psychedelic substances and their potential to heal. Hosted by Lynn Marie Morski, a physician and attorney, this podcast navigates the intricate intersection of cutting-edge science, clinical practice, and evolving policy. Each episode brings a grounded, expert perspective to conversations about psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and other compounds, moving beyond hype to examine the real-world implications of this therapeutic renaissance. Listeners will hear detailed discussions on the latest peer-reviewed research, practical insights from medical professionals integrating these approaches, and thoughtful analysis of the legal landscape shaping access. The dialogue is rooted in a commitment to safety, ethics, and evidence, offering a clear-eyed look at both the profound promise and the challenges inherent in psychedelic medicine. Whether you're a healthcare provider, a patient, a researcher, or simply intellectually curious, this podcast provides an essential, nuanced resource for understanding how these ancient and modern substances are reshaping perspectives on mental health, consciousness, and treatment. It’s a space for serious inquiry, where complex questions about healing, neuroscience, and society are met with informed, accessible conversation.
Author: Language: English Episodes: 50

Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
Podcast Episodes
Who Is a Good Candidate for Ibogaine? with Fernando Rivas, MD [not-audio_url] [/not-audio_url]

Duration: 39:32
In this episode of the Psychedelic Medicine Podcast, Fernando Rivas, MD, joins to unpack the safety and screening considerations for ibogaine therapy. Dr. Rivas is an emergency physician with over 15 years of clinical ex…
Encore Episode: Psychedelics and Breathwork with Kyle Buller [not-audio_url] [/not-audio_url]

Duration: 43:58
This encore episode of the Psychdelic Medicine Podcast features a conversation with Kyle Buller on psychedelics and breathwork. Kyle is co-founder and host of the Psychedelics Today podcast and he has studied breathwork…
Psychedelics and Psychosis with Alexander Lebedev, MD, PhD [not-audio_url] [/not-audio_url]

Duration: 46:09
In this episode of the Psychedelic Medicine Podcast, Alexander Lebedev, MD, PhD joins to discuss psychedelic medicine and psychosis. Dr. Lebedev is a physician-scientist, medical AI engineer, and entrepreneur working at…
Psychedelics and GLP-1s with Arsalan Azam, MD [not-audio_url] [/not-audio_url]

Duration: 36:22
In this episode of the Psychedelic Medicine Podcast, Arsalan Azam, MD joins to unpack the intersection between psychedelics and GLP-1s. Dr. Azam, founder of Daydream MD, completed his residency in Emergency Medicine at t…
Psilocybin vs. Ketamine with Dori Lewis, LPC [not-audio_url] [/not-audio_url]

Duration: 43:11
In this episode of the Psychedelic Medicine Podcast, Dori Lewis, MA, MEd, LPC-S returns to discuss the differences between psilocybin and ketamine. Dori is the Clinical Director of Elemental Psychedelics and Owner/Operat…
Choosing the Right Ketamine Clinic for You with Katie Fassbinder, MD [not-audio_url] [/not-audio_url]

Duration: 50:19
In this episode of the Psychedelic Medicine Podcast, Katie Fassbinder, MD joins to explore how to choose the right ketamine clinic. Dr. Fassbinder is the Faculty Medical Lead for ketamine-assisted psychotherapy training…
The Future of Psychedelic Medicine with Ismail Lourido Ali, JD [not-audio_url] [/not-audio_url]

Duration: 52:24
In the 200th episode of the Psychedelic Medicine Podcast, Ismail Lourido Ali, JD joins to discuss the future of psychedelic medicine. Ismail serves as MAPS Co-Executive Director and has been actively participating in the…
Psychedelics and Neurodiversity with Dr. WaiFung Tsang, DClinPsy [not-audio_url] [/not-audio_url]

Duration: 43:31
In this episode, Dr. WaiFung Tsang, DClinPsy joins to discuss the intersection of psychedelics and neurodiversity. Dr. Tsang is a clinical research psychologist from Hong Kong, musician, and student of Shipibo curanderis…